NOVEL SHIGELLA PROTEIN ANTIGENS AND METHODS

• US 20100124556A1
• Filed: 10/21/2009
• Published: 05/20/2010
• Est. Priority Date: 10/21/2008
• Status: Active Grant

• Current Assignee: International Vaccine Institute
• Original Assignee: International Vaccine Institute
• Inventors: Czerkinsky, Cecil, Kim, Dong Wook
• Granted Patent: US 8,147,847 B2
• Time in Patent Office: Days
• US Class Current: 424/193.100
• CPC Class Codes: A61K 2039/55566 Emulsions, e.g. Freund's adjuvant, MF59
• CPC Class Codes: A61K 2039/6037 Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
• CPC Class Codes: A61K 2039/6087 Polysaccharides; Lipopolysaccharides [LPS]
• CPC Class Codes: A61K 39/0283 Shigella
• CPC Class Codes: A61P 31/04 Antibacterial agents
• CPC Class Codes: C07K 14/25 Shigella (G)
• CPC Class Codes: Y02A 50/30 Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

The present invention relates to protein antigens IcsP2 and SigA2 from Shigella that are common among numerous Shigella types and species and which can protect against shigellosis or other enteric infections when administered as vaccines. In addition, the present invention relates to antigens that are in common between Shigella species and enteroinvasive Escherichia coli (EIEC). The invention also relates to the use of antibodies raised against these antigens and of DNA probes for use in the diagnosis of Shigella and EIEC infections.

Claims

1. A vaccine composition for immunizing a mammal against Shigella comprising an amount of Shigella proteins IcsP2 or SigA2 proteins effective to elicit an immune response against Shigella, and a pharmaceutically acceptable carrier or diluent.

9. The vaccine composition of claim 1, further comprising an adjuvant.

21. A method of treating a mammal suffering from or susceptible to a pathogenic infection caused by Shigella, comprising administering an effective amount of the vaccine composition of claim 1.

22. The method of claim 21, wherein the effective amount of the vaccine composition ranges between about 10 micrograms and about 2 milligrams.

23. A method for modulating the immune response of a mammal comprising administering an effective amount of any one of the vaccine composition of claim 1.

24. The method of claim 22, wherein the effective amount of the vaccine composition ranges between about 10 micrograms and about 2 milligrams.

2. A vaccine composition for immunizing a mammal against Shigella comprising an amount of Shigella protein IcsP2 effective to elicit an immune response against Shigella, and a pharmaceutically acceptable carrier or diluent.

3. The vaccine of claim 2 wherein said IcsP2 protein is chemically conjugated to a carrier protein.

5. The vaccine of claim 2 wherein said IcsP2 protein is the product of genetic fusion of a polynucleotide encoding the sequences of IcsP2 and the sequence of a carrier protein.

6. The vaccine of claim 5 wherein said SigA2 protein is chemically conjugated to a carrier protein.

7. The vaccine of claim 5 wherein such SigA2 protein is the product of a genetic form of a carrier and said SigA2 proteins.

8. The vaccine of claim 3, wherein the carrier protein is selected from the group consisting of tetanus toxoid, diptheria toxoid, cholera toxin B subunit, E. coli enterotoxin B subunit and flagellin.

10. The vaccine composition of claim 5, further comprising an adjuvant wherein said adjuvant is an oil phase of an emulsion selected from a group consisting of a water-in-oil emulsion and a double oil emulsion.

35. The vaccine composition of claim 2, further comprising an adjuvant.

37. A method of treating a mammal suffering from or susceptible to a pathogenic infection caused by Shigella, comprising administering an effective amount of the vaccine composition of claim 2.

4. A vaccine composition for immunizing a mammal against Shigella comprising an amount of Shigella SigA2 effective to elicit an immune response against Shigella, and a pharmaceutically acceptable carrier or diluent.

36. The vaccine composition of claim 4, further comprising an adjuvant.

38. A method of treating a mammal suffering from or susceptible to a pathogenic infection caused by Shigella, comprising administering an effective amount of the vaccine composition of claim 4.

11-20. -20. (canceled)

25-34. -34. (canceled)